Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 49, 2019 - Issue 9
189
Views
12
CrossRef citations to date
0
Altmetric
Xenobiotic transporters

Dioscorea bulbifera L. delays the excretion of doxorubicin and aggravates doxorubicin-induced cardiotoxicity and nephrotoxicity by inhibiting the expression of P-glycoprotein in mice liver and kidney

ORCID Icon, , , , , , & show all
Pages 1116-1125 | Received 24 May 2018, Accepted 05 Jul 2018, Published online: 15 May 2019

References

  • Abou EI Hassan MA, Kedde MA, Zwiers UT. (2003). The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice. Cancer Chemother Pharmacol 51:306–10.
  • Cappetta D, Rossi F, Piegari E, et al. (2018). Doxorubicin targets multiple players: a new view of an old problem. Pharmacol Res 127:4–14.
  • Chen N, Cui D, Wang Q, et al. (2018). In vitro drug–drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes. Xenobiotica 48:637–46.
  • Choi YH, Lee YK, Lee MG. (2013). Effects of 17 α-ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: reduced biliary excretion and hepatic metabolism of doxorubicin. Xenobiotica 43:901–7.
  • Durmus S, Naik J, Buil L, et al. (2014). In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. Int J Cancer 135:1700–10.
  • El-sherbiny NM, El-Sherbiny M. (2014). Thymoquinone attenuates doxorubicininduced nephrotoxicity in rats: role of Nrf2 and NOX4. Chem Biol Interact 223:102–8.
  • Kim TH, Shin S, Yoo SD. (2018). Effects of phytochemical P-Glycoprotein modulators on the pharmacokinetics and tissue distribution of doxorubicin in mice. Molecules 23:E349.
  • Komori Y, Arisawa S, Takai M, et al. (2014). Ursodeoxycholic acid inhibits overexpression of P-glycoprotein induced by doxorubicin in HepG2 cells. Eur J Pharmacol 724:161–7.
  • Li R, Barton HA, Varma MV. (2014). Prediction of pharmacokinetics and drug–drug interactions when hepatic transporters are involved. Clin Pharmacokinet 53:659–78.
  • Lund M, Petersen TS, Dalhoff KP, et al. (2017). Clinical implications of P-glycoprotein modulation in Drug-Drug Interactions. Drugs 77:859–883.
  • Meng Q, Liu K. (2014). Pharmacokinetic interactions between herbal medicines and prescribed drugs: focus on drug metabolic enzymes and transporters. Curr Drug Metab 15:791–807.
  • Mohajeri M, Sahebkar A. (2018). Protective effects of curcumin against doxorubicininduced toxicity and resistance: A review. Crit Rev Oncol Hematol 122:30–51.
  • Niu C, Wang J, Ji L, et al. (2014). Protection of Angelica sinensis (Oliv) Diels against hepatotoxicity induced by Dioscorea bulbifera L. and its mechanism. Biosci Trends 8:253–9.
  • Patel KJ, Tannock IF. (2009). The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 9:356
  • Pfizer Inc. (2013). Prescribing information for doxorubicin hydrochloride. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/ 050467s073lbl.pdf [last accessed 19 Jul 2018].
  • Pugazhendhi A, Edison TNJI, Velmurugan BK, et al. (2018). Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci 200:26–30.
  • Qu XY, Tao LN, Zhang SX, et al. (2017). The role of Ntcp, Oatp2, Bsep and Mrp2 in liver injury induced by Dioscorea bulbifera L. and Diosbulbin B in mice. Environ Toxicol Pharmacol 51:16–22.
  • Romagnoli KM, Nelson SD, Hines L, et al. (2017). Information needs for making clinical recommendations about potential drug–drug interactions: a synthesis of literature review and interviews. BMC Med Inform Decis Mak 17:21
  • Sheng Y, Ma Y, Deng Z, et al. (2014). Cytokines as potential biomarkers of liver toxicity induced by Dioscorea bulbifera L. Biosci Trends 8:32–7.
  • Szwed M, Kania KD, Jozwiak Z. (2014). Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin. Cell Oncol (Dordr) 37:421–8.
  • Tachibana T, Kato M, Takano J, et al. (2010). Predicting drug–drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein . Curr Drug Metab 11:762–77.
  • Wei W, Wu XM, Li YJ. 2010. Experimental Methodology of Pharmacology. 4th ed. Beijing, PR China: People’s Medical Publishing House.
  • Yang F, Liang Y, Xu L, et al. (2016). Exploration in the cascade working mechanisms of liver injury induced by total saponins extracted from Rhizoma Dioscorea Bulbifera. Biomed Pharmacother 83:1048–56.
  • Zhang Y, Xu Y, Qi Y, et al. (2017). Protective effects of dioscin against doxorubicininduced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation. Toxicology 378:53–64.
  • Zhao L, Tao X, Qi Y, et al. (2018). Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial oxidative stress. Redox Biol 16:189–98.
  • Zhao L, Qi Y, Xu L, et al. (2018). MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biol 15:284–96.
  • Zheng WY, Richardson LC, Li L, et al. (2018). Drug–-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 74:15–27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.